A P2Y12 inhibitor, such as clopidogrel or ticagrelor, might be a better choice than aspirin for antiplatelet monotherapy in patients with coronary artery disease, results of a new meta-analysis suggest.
The PANTHER meta-analysis showed that P2Y12 inhibitor treatment lowered the risk for subsequent ischemic events, particularly myocardial infarction (MI), compared...